More Adalta Ltd. news Adalta Ltd.ASX: 1AD 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer Oct 13, 2022 at 1:40 AM UTC · Issued by Adalta Ltd. As issuedPlain English Adalta Ltd has released a press release. View Attachment
